Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy

Author(s)

Da Silva, Lais Teodoro ; Tiyo, Bruna Tiaki ; Mota, Silvia de Jesus ; Ortega, Marina Mazzilli ; Schmitz, Gabriela Justamante Handel ; Taniwaki, Noemi Nosomi ; Nishina, Gislene Mitsue Namiyama ; Duarte, Alberto Jose da Silva ; Oshiro, Telma Miyuki

• Document type: Journal article
• Source: JOURNAL OF IMMUNOLOGY RESEARCH; v. 2024, p. 11-pg., 2024-06-07.

Abstract

Therapeutic vaccines based on monocyte-derived dendritic cells have been shown to be promising strategies and may act as complementary treatments for viral infections, cancers, and, more recently, autoimmune diseases. Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70). In the clinical use of cell-based therapeutics, injectable solutions can affect the morphology, immunophenotypic profile, and viability of cells before delivery and their survival after injection. In this sense, preparing a cell suspension that maintains the quality of aDC1s is essential to ensure effective immunotherapy. In the present study, monocytes were differentiated into aDC1s in the presence of IL-4 and GM-CSF. On day 5, the cells were matured by the addition of a cytokine cocktail consisting of IFN-alpha, IFN-gamma, IL-1 beta, TNF-alpha, and Poly I:C. After 48 hr, mature aDC1s were harvested and suspended in two different solutions: normal saline and Ringer's lactate. The maintenance of cells in suspension was evaluated after 4, 6, and 8 hr of storage. Cell viability, immunophenotyping, and apoptosis analyses were performed by flow cytometry. Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22 degrees C. (AU)

• FAPESP's process: 19/24849-1 - Nanoparticles as HIV antigen delivery: potential application in anti-HIV immunotherapy using monocyte-derived dendritic cells
• Grantee: Bruna Tiaki Tiyo
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 23/11990-3 - Production and characterization of polarized dendritic cells aDC1 for use in anti-HIV immunotherapy
• Grantee: Laís Teodoro da Silva
• Support Opportunities: Scholarships in Brazil - Technical Training Program - Technical Training
• FAPESP's process: 18/12460-0 - Production and characterization of polarized dendritic cells aDC1 for use in anti-HIV immunotherapy
• Grantee: Laís Teodoro da Silva
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 14/50489-9 - Human thymus: development and diseases
• Grantee: Magda Maria Sales Carneiro-Sampaio
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 16/25212-9 - Therapeutic vaccine based on aDC1 dendritic cells pulsed with inactivated autologous virus for the control of viremia after ATI in HIV infected individuals
• Grantee: Alberto José da Silva Duarte
• Support Opportunities: Research Projects - Thematic Grants